MediWound (MDWD) shares ended the last trading session 8.5% higher at $19.83. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.5% gain over the past four weeks.
The sudden stock price rise can be attributed to positive investor expectations regarding the company’s pipeline potential. MediWound is currently developing EscharEx in mid to late-stage studies for treating various ulcer indications. A regulatory filing seeking the approval of the candidate for venous leg ulcers is expected in 2025. Another candidate, MW005 is also currently undergoing mid-stage development for non-melanoma skin cancer. MediWound currently markets NexoBrid which is approved for eschar removal in adult and pediatric patients with deep partial thickness and/or full thickness thermal burns in several geographies including the United States. Investors also likely expect an increase in year-over-year sales of the product in the upcoming quarterly release.
This developer of treatments for burns and hard-to-heal wounds is expected to post quarterly loss of $0.61 per share in its upcoming report, which represents a year-over-year change of -221.1%. Revenues are expected to be $5.8 million, up 8.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For MediWound, the consensus EPS estimate for the quarter has been revised 0.6% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on MDWD going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
MediWound is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Nektar Therapeutics (NKTR), finished the last trading session 1.1% lower at $0.88. NKTR has returned -6% over the past month.
For Nektar
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpMediWound Ltd. (MDWD) : Free Stock Analysis Report
Nektar Therapeutics (NKTR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
